NGM Bio is named one of FierceBiotech's "Fierce 15" Biotech Companies of 2015

NGM Bio is named one of FierceBiotech's "Fierce 15"
Biotech Companies of 2015

SOUTH SAN FRANCISCO, CA, September 30, 2015 – NGM Bio, a privately held biotechnology company that seeks to translate powerful biology into transformative medicines, today announced that it has been named by FierceBiotech as one of 2015's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry.

"We are honored to be included in the Fierce 15 class of 2015," said William Rieflin, Chief Executive Officer of NGM Bio. "Credit must go to our terrific team of drug hunters who have spent the last seven years discovering and developing our pipeline of first-in-class biologics, including the four clinical candidates that we are developing to treat a range of serious liver and cardio-metabolic diseases."

The Fierce 15 celebrates the spirit of being "fierce" – championing innovation and creativity, even in the face of intense competition. This is FierceBiotech's thirteenth annual Fierce 15 selection. A complete list of "Fierce 15" companies can be found online at 

An internationally recognized daily report reaching a network of over 275,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with an authoritative analysis of the day's top stories. Every year FierceBiotech evaluates hundreds of private companies from around the world for its annual Fierce 15 list, which is based on a variety of factors such as the strength of its technology, partnerships, venture backers and a competitive market position.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor, an email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval, FDA regulation, patent news, pharma news, biotech company news and more. More than 150,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day's top stories. Signup is free at

About NGM Biopharmaceuticals

NGM Bio applies fundamental discoveries in human pathophysiology to create novel biologics for the treatment of a broad spectrum of life-threatening diseases. NGM Bio's lead compound, NGM282, a wholly owned asset, is being studied in primary sclerosing cholangitis and nonalcoholic steatohepatitis. Three additional clinical candidates, NGM386, NGM395 and NGM313, are part of a broad collaboration with Merck and are in development as potential treatments for cardio-metabolic diseases and nonalcoholic steatohepatitis. NGM Bio also has established collaborations with MedImmune and JDRF. NGM Bio is a privately held company backed by investments from The Column Group, Merck, Prospect Ventures, Rho Ventures, Tichenor Ventures, Topspin Partners and other leading investors around the world. For more information, please visit



Rebecca Friend



[email protected]


Laura Bagby                       

6 Degrees Communications


[email protected]


Hannah Deresiewicz

Stern Investor Relations, Inc.


[email protected]